What is Revolution Medicines Financial Strength?
Revolution Medicines has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Revolution Medicines did not have earnings to cover the interest expense.
Revolution Medicines's debt to revenue ratio for the quarter that ended in Dec. 2023 was 29.63.
As of today, Revolution Medicines's Altman Z-Score is 16.18.
Competitive Comparison of Revolution Medicines's Financial Strength
For the Biotechnology subindustry, Revolution Medicines's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revolution Medicines's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revolution Medicines's Financial Strength distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's Financial Strength falls into.
Revolution Medicines Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Revolution Medicines's Interest Expense for the
months ended in Dec. 2023 was $-0.30 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-179.98 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $80.58 Mil.
Revolution Medicines's Interest Coverage for the quarter that ended in Dec. 2023 is
| Revolution Medicines did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Revolution Medicines's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Revolution Medicines has a Z-score of 16.18, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 16.18 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (Revolution Medicines) Business Description
Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Executives
| Stephen Michael Kelsey |
officer: See Remarks |
C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
| Jeff Cislini |
officer: General Counsel |
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Mark A Goldsmith |
director, officer: See Remarks |
925 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Margaret A Horn |
officer: See Remarks |
925 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Jack Anders |
officer: Chief Financial Officer |
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Barbara Weber |
director |
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Xiaolin Wang |
officer: See Remarks |
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Thilo Schroeder |
director |
C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001 |
| Lorence H. Kim |
director |
C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472 |
| Sushil Patel |
director |
C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801 |
| Third Rock Ventures Iii, L.p. |
10 percent owner |
29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
| Flavia Borellini |
director |
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Third Rock Ventures Ii, L.p. |
10 percent owner |
29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
| Peter Svennilson |
director, 10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Vincent A. Miller |
director |
C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139 |
Revolution Medicines (Revolution Medicines) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVMD has been successfully added to your